Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 84 | ETA2022 | Next issue

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

Card image cap

Oral Presentations

Oral Session 7: Thyroid Cancer Basic

ea0084op-07-32 | Oral Session 7: Thyroid Cancer Basic | ETA2022

The micro-rna content of extracellular vesicles in papillary thyroid cancer: from identification in mouse thyroid tumour to detection in patient plasma

Delcorte Ophelie , Spourquet Catherine , Pascale Lemoine , Pierreux Christophe

Background: Papillary thyroid carcinoma (PTC) is the most frequent subtype of thyroid cancers. Despite good prognosis in most cases, postsurgery recurrences and metastases can occur. Moreover, differential diagnosis between benign and malignant nodules is still challenging. Gaining knowledge about extracellular vesicles (EVs) in PTC could have a double benefit: a better understanding of PTC clinical behaviour, and the discovery of accessible (and accurate) diagnostic tools.</p...

ea0084op-07-33 | Oral Session 7: Thyroid Cancer Basic | ETA2022

HüRthle cell tumors vs oncocytic variants of the follicular cell derived thyroid tumours: a comprehensive analysis based in transcriptome, proteome and cnv profiling

Canberk Sule , ferreira marta , Oliveira Carla , reis joana , barros rita , pereira luisa , osorio hugo , Rios Elisabete , Soares Paula , Maximo Valdemar

Objectives: Hürthle cell (oncocytic) lesions can be metaplastic or neoplastic events. The neoplastic entities -formerly, oncocytic variant of follicular tumours; Hürthle cell neoplasm (HCN) - include HC adenomas and HC carcinomas and have been recognized as a separate class of tumours by the WHO. The remaining of the thyroid tumours demonstrating “mitochondrion-rich cells” and oncocytic morphology are referred under the umbrella term of “oncocytic vari...

ea0084op-07-34 | Oral Session 7: Thyroid Cancer Basic | ETA2022

CDK4 phosphorylation status and rational use of CDK4/6 inhibitors in advanced thyroid cancers

Pita Jaime M , Coulonval Katia , Costante Giuseppe , Myriam Decaussin , Emmanuelle Leteurtre , Cavaco Branca , A Copland John , Durante Cosimo , Maenhaut Carine , Dumont Jacques , Roger Pierre , Raspe Eric

Introduction and objectives: The cyclin-dependent kinases CDK4 and CDK6 are key regulators of the cell cycle entry, by phosphorylating the onco-suppressor retinoblastoma protein (pRb). CDK4/6 inhibitors (CDK4i) are already established as standard first-line treatment against advanced Estrogen Receptor-positive breast tumors, and have emerged as novel drugs to treat various pRb-proficient chemotherapy-resistant cancers. Presence of activating T172-phosphorylation of CDK4 in bre...

ea0084op-07-35 | Oral Session 7: Thyroid Cancer Basic | ETA2022

RET fusion genes in a large cohort of papillary thyroid carcinomas

Pekova Barbora , Sykorova Vlasta , Mastnikova Karolina , Vaclavikova Eliska , Moravcova Jitka , Vlcek Petr , Katra Rami , Lastuvka Petr , Bavor Petr , Kodetova Daniela , Chovanec Martin , Drozenova Jana , Astl Jaromir , Hrabal Petr , Vcelak Josef , Bendlova Bela

Objectives: RET fusion genes are known driver mutations in papillary thyroid carcinomas (PTCs) and have been described mainly in pediatric PTCs, in which they represent the most common genetic alteration. The aims of this study were to identify RET fusion genes in PTCs (from pediatric as well as adult patients), to correlate them with clinical and histopathological features and to determine the prognostic significance of RET fusion genes based on lon...

ea0084op-07-36 | Oral Session 7: Thyroid Cancer Basic | ETA2022

Loss of tumor cell MHC class ii expression as driver of relapse to dabrafenib and trametinib in mouse BRAF-mutant anaplastic thyroid cancer

Tiedje Vera , Qin Tianyue , Im Soo-Yeon , P Krishnamoorthy Gnana , A. Knauf Jeffrey , A. Fagin James

Objectives: BRAFV600E- anaplastic thyroid cancers (ATCs) show remarkable responses to dabrafenib and trametinib (dab/tram) an effect that may be in part immune-mediated. Murine BRAFV600E-ATCs regress upon BRAF inhibition. We find that recurrences are frequent and associated with loss of Mhc class II (MhcII) expression. Our goal was to investigate the mechanisms of loss of antigen presentation by tumor cells and whether this contributes to disease recurren...